Artificial intelligence is an advanced method to identify novel anticancer targets and discover
novel drugs from biology networks because the networks can effectively preserve and …

Cancer is the second leading cause of death globally, trailing only heart disease. In the
United States alone, 1.9 million new cancer cases and 609,360 deaths were recorded for …

Recent technological advances and international efforts, such as The Cancer Genome Atlas
(TCGA), have made available several pan-cancer datasets encompassing multiple omics …

High-throughput technologies used in molecular biology have been pivotal to enhance the
molecular characterization of human malignancies, allowing multiple omics data types to be …

Background Patient subgroups are important for easily understanding a disease and for
providing precise yet personalized treatment through multiple omics dataset integration …

Most national health-care systems approve new drugs based on data of safety and efficacy
from large randomized clinical trials (RCTs). Strict selection biases and study-entry criteria of …

Tumour heterogeneity is one of the main characteristics of cancer and can be categorised
into inter‐or intratumour heterogeneity. This heterogeneity has been revealed as one of the …

The response variation to anti-cancer drugs originates from complex intracellular network
dynamics of cancer. Such dynamic networks present challenges to determining optimal drug …

The Wnt pathway is important to regulate a variety of biochemical functions and can
contribute to cancer development through its influence on the epithelial-mesenchymal …

Background and Objectives: Over decades, prostate cancer (PCa) has become one of the
leading causes of cancer mortality in men. Extensive evidence exists that microRNAs …